Stock Price
61.34
Daily Change
-0.08 -0.13%
Monthly
-5.95%
Yearly
-26.61%
Q1 Forecast
60.90



Peers Price Chg Day Year Date
AstraZeneca 13,980.00 184.00 1.33% 18.62% Feb/05
Bayer 44.82 -0.34 -0.74% 111.19% Feb/05
Essilor 258.60 -2.00 -0.77% -4.47% Feb/05
Fresenius Medical Care 40.48 0.21 0.52% -13.91% Feb/05
Fresenius 49.24 0.01 0.02% 34.28% Feb/05
GRIFOLS 10.84 -0.21 -1.86% 28.19% Feb/05
GlaxoSmithKline 2,180.00 100.00 4.81% 47.35% Feb/05
Lonza 518.20 -7.80 -1.48% -15.46% Feb/05
Merck 122.05 -1.80 -1.45% -14.20% Feb/05
Novartis 119.28 0.58 0.49% 22.08% Feb/05

Indexes Price Day Year Date
CH20 13466 -42.08 -0.31% 6.67% Feb/05
EU600 612 -6.46 -1.05% 12.26% Feb/05

Alcon AG traded at 61.34 this Thursday February 5th, decreasing 0.08 or 0.13 percent since the previous trading session. Looking back, over the last four weeks, Alcon AG lost 5.95 percent. Over the last 12 months, its price fell by 26.61 percent. Looking ahead, we forecast Alcon AG to be priced at 60.90 by the end of this quarter and at 56.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.